Business
Xeris Pharmaceuticals shares latest product and partnership updates
--News Direct--Xeris Pharmaceuticals chairman and CEO Paul Edick joins Natalie Stoberman from the Proactive studios to discuss the latest updates on product
About this update from Xeris Biopharma Holdings, Inc.
[{"type":"text","content":"--News Direct--Xeris Pharmaceuticals chairman and CEO Paul Edick joins Natalie Stoberman from the Proactive studios to discuss the latest updates on product line performance. Xeris is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis, a proven therapy for primary periodic paralysis; and Recorlev for the treatment of endogenous Cushing’s syndrome. Xeris has a pipeline of development and partnered programs using its formulation sciences, XeriSol and XeriJect, to support long-term product development and commercial success. Contact DetailsProactive Investors+1 [email protected] source version on newsdirect.com: https://newsdirect.com/news/xeris-pharmaceuticals-shares-latest-product-and-partnership-updates-413821847","length":1566,"tagName":"div"}]